Abstract: A feed supplement for ruminants to increase milk production, comprised of a carrier and the reaction product of a water soluble polycarboxylic acid, a metal salt, and a C3 to C10 fatty acid, the water soluble carboxylic acid having a pendant carboxylic acid group and being linked to the metal of the metal salt, which is in turn linked to the C3 to C10 fatty acid.

Abstract: A feed supplement energy source for ruminants, swine and poultry comprised of a carrier and the reaction product of a water soluble polycarboxylic acid, a metal salt, and a C3 to C10 fatty acid, the water soluble carboxylic acid having a pendant carboxylic acid group and being linked to the metal of the metal salt, which is in turn linked to the C3 to C10 fatty acid.

Abstract: The present invention relates to the use as perfuming ingredient, in particular to confer odor notes of the violet, violet leaves type, of a compound of formula (I), wherein n represents 1 or 2, A represents CH2 or CO; and R represents a C1-4 alkyl or alkenyl group or a C3 cycloalkyl group, or when A is a CH2 group R may also represent a C1-3 acyl group. Moreover, following what is mentioned herein, the present invention comprises the invention's compound as part of a perfuming composition or of a perfuming consumer product.

Abstract: There is provided a cosmetic additive in which the cosmetic obtained by mixing has excellent transparency, and good spread and feeling of use during application, and stickiness when dried can be suppressed, and a cosmetic containing the additive. A cosmetic additive containing cellulose fibers having an average fiber diameter (D) of 0.001 to 0.05 ?m, and a ratio (L/D) of average fiber length (L) to average fiber diameter (D) of 5 to 500; and a cosmetic containing the cosmetic additive.

Abstract: Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer.

Abstract: Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a teat seal formulation including a metal salt in a glyceride-containing gel base into the teat canal of the animal. The method also prevents the formation of black spot defect in dairy products, especially cheddar cheese, made from the milk of animals so treated.

Abstract: The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction.

Abstract: The present invention provides methods of lyophilizing a pharmaceutical substance involving a primary drying step executed at a product temperature at or above the collapse temperature. The invention also provides pharmaceutical substances lyophilized at or above the collapse temperature.

Abstract: This invention relates to a granulate comprising mannitol and sorbitol in a weight ratio of between 70:30 and 97:3. This invention also relates to the use of a granulate in the preparation of orodispersible tablets, to the orodispersible tablets obtained with a granulate and to a process of for producing a granulate.

Abstract: A skin external preparation includes a finely dispersed wax composition that is solid or semisolid at room temperature, a nonionic surfactant, an aqueous dispersion medium, and an ionic water-soluble thickener, and optionally further contains at least one of silicone oil and fluorinated oil which is liquid at room temperature, and the mass ratio of the nonionic surfactant to the wax being 1.0 or more, the particle size of the finely dispersed wax is 500 nm or less, and it substantially contains no ionic surfactants therein.

Abstract: The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable water soluble acid and its use for the treatment of essential thrombocythemia.

Abstract: A flowable, stable silica capsule formulation composed of a silica capsule suspension and an adjuvant for use in a personal care product, a beauty care product, a fabric care product, a home care product, a personal hygiene product, an oral care product is provided.

Abstract: The present invention relates to an emulsion concentrate containing water-insoluble oil components (A), hydrophilic non-ionic emulsifiers (B), lipophilic co-emulsifiers (C), polyols (D) and water; which comprises less than 50% by weight of water-insoluble oil component (A), based on the total weight of the concentrate, and comprises components (A), (B) and (C) and (D) in a ratio by weight A:B:C:D=1:(0.25-0.6):(0.25-0.6):(0.45-0.65). The invention further relates to the use of these emulsion concentrates, and also to preparations and paper products, non-woven products or textile products for body care and personal cleansing, which comprise water-insoluble oil components (A), hydrophilic non-ionic emulsifiers (B), lipophilic co-emulsifiers (C), and polyols (D) in a ratio by weight A:B:C:D=1:(0.25-0.6):(0.25-0.6):(0.45-0.65).

Abstract: A water-based pigmented preparation, its production and use and its application in a capillary storage system.

Abstract: Disclosed is the use of an insoluble or sparingly soluble micronized substance class which is not a cosmetic UV absorber and which is dispersed in the oil- or water-phase of a cosmetic or dermatological composition for the enhancement of light protecting action of this cosmetic or dermatological composition comprising at least one cosmetic UV filter which is soluble in the water- or oil-phase. The cosmetic preparation according to the invention shows a remarkable increase in SPF.

Abstract: A water-based pesticidal suspension comprises (a) flonicamid, (b) a polycarboxylate surfactant, (c) a sulfonate surfactant, and (d) water. The sulfonate surfactant (c) is at least one member selected from the group consisting of an alkyl sulfosuccinate, a lignosulfonate, a C8-18 alkyl benzene sulfonate and a C8-18 alkyl diphenyl ether disulfonate. An average particle size of the volume distribution of (a) flonicamid is preferably from 0.5 ?m to 10 ?m. The polycarboxylate surfactant (b) is preferably a sodium salt of maleic acid/olefin copolymer.

Abstract: The present invention is related to aqueous conditioning composition for hair comprising at least one cationic starch polymer and at least one additional cationic polymer selected from the ones with monosaccharide units. Conditioning composition of the present invention can be in the form of a shampoo, cleansing-conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions.

Abstract: The present invention provides a solid dosage form including an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating; wherein the inner coating includes a partially neutralized anionic polymeric material, and at least a carboxylic acid having 2 to 16 carbon atoms the salts thereof or mixtures of the acid and its salt; wherein the outer coating includes an anionic polymeric material which is less or not at all neutralized than the material of the inner coating.

Abstract: A suspension which is suitable for oral administration, comprising simvastatin, at least one suspending agent, and at least one preservative, wherein at least 90 wt % of the particles of simvastatin are less than 100 ?m in diameter. The present invention also includes uses of the suspension and methods of making the suspension.

Abstract: The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction.